Postchallenge Glucose, A1C, and Fasting Glucose as Predictors of Type 2 Diabetes and Cardiovascular Disease

A 10-year prospective cohort study

HENNA CEDERBERG, MD1
TUULA SAUKKONEN, MD, MSC1,2
MAURI LAAKSO, MD1,3
JARI JOKELAINEN, MSC1,3
PİRJO HÄRKÖNEN, MNSC4
MARKKU TIMONEN, MD, PhD1
SIRIKA KEINÄNEN-KIUKANEN, MD, PhD1,3,5
ULLA RAJALA, MD, PhD1

OBJECTIVE — A1C has been proposed as a new indicator for high risk of type 2 diabetes. The long-term predictive power and comparability of elevated A1C with the currently used high-risk indicators remain unclear. We assessed A1C, impaired glucose tolerance (IGT), and impaired fasting glucose (IFG) as predictors of type 2 diabetes and cardiovascular disease (CVD) at 10 years.

RESEARCH DESIGN AND METHODS — This prospective population-based study of 593 inhabitants from northern Finland, born in 1935, was conducted between 1996 and 2008. An oral glucose tolerance test (OGTT) was conducted at baseline and follow-up, and A1C was determined at baseline. Those with a history of diabetes were excluded from the study. Elevated A1C was defined as 5.7–6.4%. Incident type 2 diabetes was confirmed by two OGTTs. Cardiovascular outcome was measured as incident CVD or CVD mortality. Multivariate log-binomial regression models were used to predict diabetes, CVD, and CVD mortality at 10 years. Receiver operating characteristic curves compared predictive values of A1C, IGT, and IFG.

RESULTS — Incidence of diabetes during the follow-up was 17.1%. Two of three of the cases of newly diagnosed diabetes were predicted by a raise in ≥1 of the markers. Elevated A1C, IGT, or IFG preceded diabetes in 32.8, 40.6, and 21.9%, respectively. CVD was predicted by an increase in A1C, IGT, and IFG.

CONCLUSIONS — A1C predicted 10-year risk of type 2 diabetes at a range of A1C 5.7–6.4% but CVD only in women at A1C ≥6.5%.

Diabetes Care 33:2077–2083, 2010

Early detection of high risk for type 2 diabetes is fundamental for prevention of diabetes and associated cardiovascular complications. Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) are currently used for diagnosis of high-risk glucose levels below the diabetic range. The International Expert Committee proposed A1C ≥6.5% as a diagnostic tool for diabetes in 2009 (1) and in January 2010 an intermediate range of A1C 5.7–6.4% (elevated A1C) was proposed by the American Diabetes Association (ADA) to detect individuals at high risk for developing type 2 diabetes (2).

To date, however, limited data exist to support the use of A1C in predicting type 2 diabetes (3–8). Importantly, the long-term predictive power of elevated A1C as defined above has not yet been investigated. Previous data on the association between A1C and incident type 2 diabetes in unselected populations have relied on self-reporting, fasting glucose measurements, and use of antidiabetes medication to determine the outcomes. An oral glucose tolerance test (OGTT) has not been used to determine the outcome (3–8).

Deterioration of glucose homeostasis reflects a continuum of glycemia, some of which is reversible if detected early (9,10). Importantly, the risk of cardiovascular disease is increased already before glycemia reaches the levels of diabetes, and 2-h glucose appears to be a better predictor of cardiovascular disease (CVD) than fasting glucose (11). Recently, A1C was shown to be a better predictor of CVD than fasting glucose (12).

Data directly comparing 2-h glucose and A1C as long-term predictors of new-onset cardiovascular disease are scarce, and results are controversial (13,14). Therefore, we compared A1C, 2-h glucose, and fasting glucose as predictors of type 2 diabetes, CVD, and CVD mortality during a prospective population-based study with a 10-year follow-up.

RESEARCH DESIGN AND METHODS — This study conducted in 1996–2008 is part of a longer follow-up study assessing type 2 diabetes and IGT, in which all inhabitants of city of Oulu, Finland, born in 1935 were invited to participate. Between 1996 and 1998, 831 were invited, of whom 593 (245 men) enrolled. Formation of the study population is shown in Fig. 1. Recruitment process and methods have been described previously (15). Type 2 diabetes was confirmed by two diabetic 2-h and/or fasting values. There were no significant differences in sex, baseline glucose status, anthropometric measurements, blood pressure, or lipid profile between the participants and nonparticipants. A higher prevalence of current smoking was observed among nonparticipants (28.9 vs. 20.5%).
14.0%; P < 0.05). The study protocol was approved by the Ethics Committee of the Faculty of Medicine, University of Oulu, Oulu, Finland.

**Procedures**

A standardized 75-g OGTT was performed in 1996–1998 and 2007–2008. After a 12-h overnight fast, venous blood samples were drawn between 8:00 and 10:00 AM for fasting glucose and also for A1C at baseline. After ingestion of a 75-g liquid glucose load, a blood sample was drawn for 2-h glucose. At baseline, the fasting value was determined from whole blood and 2-h glucose was determined from a capillary sample in accordance with contemporary guidelines (16). Capillary samples were analyzed immediately after collection. At follow-up, venous plasma, drawn in containers with glycolytic inhibitors and centrifuged immediately to separate plasma, according to the World Health Organization (WHO) 2006 recommendations (17), was used for both glucose measurements. Glucose concentration was determined using the hexokinase-glucose-6-phosphate dehydrogenase method. A1C was analyzed with a Bayer DCA2000 analyzer, calibrated to the Diabetes Control and Complications Trial standard (18).

Clinical examination was conducted by a trained research nurse. Height (centimeters) and weight (kilograms) were measured with the individual in light
cognition, and BMI (weight in kilograms divided by the square of height in meters) was calculated. Participants completed questionnaires on smoking, alcohol consumption, and exercise. Smoking was quantified (number of cigarettes and years smoked), and smoking status was classified into current or nonsmokers. Alcohol consumption was quantified (units per week), and alcohol status was classified as abstainer or user. Exercise behavior was determined by asking participants about the frequency and duration of exercise and was classified as active or inactive, as described elsewhere (19).

**Cardiovascular and mortality outcomes**

Incidence of CVD and CVD mortality was evaluated from date of the baseline OGTT in 1996–1998 to 1 May 2009. Cardiovascular diagnoses (coded according to ICD-10: 100–199) were obtained from the Oulu University Hospital discharge register for inpatient and outpatient visits. The prevalence of CVD was self-reported by participants at baseline. All participants live in the catchment area of the same tertiary care center, and any cardiovascular symptoms requiring hospital care were thus treated in the same center. Information on deaths was obtained from official death certificates (obtained from Statistics, Finland), coded according to ICD-10.

**Statistical analysis**

Glucose tolerance status was classified according to the WHO 1999 criteria (16). Because of the low number of individuals with combined IFG and IGT, this group was included in the IGT group for analysis. Baseline characteristics of groups were compared with t tests and the Mann-Whitney U test, where appropriate. Categorical variables, presented as percentages, were compared with a $\chi^2$ test. Associations between fasting and 2-h glucose, A1C and incident type 2 diabetes, and CVD were analyzed with log-binomial regression. Crude and adjusted relative risks with 95% CI are presented. Predictive properties of fasting and 2-h glucose and A1C for incident type 2 diabetes were evaluated with receiver operating characteristic curves. Areas under the receiver operating characteristic curves (AUCs) were calculated and compared with a nonparametric method (20). All data were analyzed with Stata (version 11MP).

**RESULTS**— Breakdown of glucose tolerance status of the cohort at baseline was 74.1, 18.7, 7.2, and 2.7% for normal glucose tolerance, IGT, IFG, and combined IGT and IFG, respectively. During the follow-up (mean ± SD time of 9.7 ± 0.7 years), incidence of type 2 diabetes was 17.1% ($n = 64$).

Characteristics of the cohort at baseline and follow-up are shown (Table 1). Participants who developed type 2 diabetes had higher fasting glucose, 2-h glucose, and A1C at baseline ($P < 0.0001$) and higher BMI at baseline ($P < 0.0005$) compared with those who remained nondiabetic.

The proportion of individuals who developed diabetes during the follow-up was similar in all groups (37.8% of subjects with IFG, 37.1% with IGT, and 37.5% with elevated A1C, respectively). Crude risk ratios (RRs) of risk of diabetes were relatively similar for IFG (RR 2.56 [95% CI 1.57–4.16]), IGT (2.98 [1.94–4.56]), and elevated A1C (2.78 [1.80–4.31]). When adjusted for sex, BMI at baseline, smoking, alcohol, and exercise, corresponding RRs were 2.37 [1.49–3.78], 2.90 [1.90–4.43], and 2.42 [1.50–3.91] for IFG, IGT, and A1C, respectively.

Breakdown of type 2 diabetes as predicted by the three tests is illustrated in Fig. 2. In total, 65.7% of the cases of newly diagnosed diabetes were predicted by a raise in ≥1 markers at baseline. The most common condition to precede diabetes was IGT (40.6%), followed by elevated A1C (32.8%), followed by IFG (21.9%). An elevation in an isolated marker predicted type 2 diabetes in a remarkable number of subjects. Percentages of isolated IGT, isolated elevated A1C, and isolated IFG preceding diabetes were 23.4%, 14.1% and 6.3%, respectively ($P = 0.31$). A relatively small percentage of cases of diabetes were preceded by a combination of two markers, with all three elevated in only 7.8% of participants who developed diabetes. Specificity of IGT, IFG, and A1C for incident type 2 diabetes was 85.9–92.6% (Fig. 3). AUC ranged from 0.69 for 2-h glucose to 0.61 for fasting glucose ($P = 0.36$ for equality).

Total incidence of new CVD was 37.6% and according to sex, 34.3% in women and 42.7% in men. In women, 32% with A1C ≥ 6.5% developed CVD (RR 0.96 [95% CI 0.62–1.49] and 2.99 [2.50–

| Table 1—Characteristics of the cohort by sex at baseline (1996–1998) and at follow-up (2007–2008) |
|---------------------------------|-----------------|-----------------|-----------------|
|                                | Men             | Women           | P value         |
|--------------------------------|-----------------|-----------------|-----------------|
| **Baseline**                   |                 |                 |                 |
| $n$                            | 223             | 330             |                 |
| Screen detected type 2 diabetes (%) | 10.3           | 08.5            | 0.4659          |
| BMI (kg/m$^2$)                 | 27.6 ± 3.5      | 27.9 ± 4.5      | 0.4492          |
| Current smokers (%)            | 18.4            | 14.9            | 0.2773          |
| Alcohol use (%)                | 84.3            | 70.0            | 0.0001          |
| Physically inactive (%)        | 28.2            | 23.7            | 0.2432          |
| Diastolic blood pressure (mmHg) | 79.5 ± 7.6      | 78.8 ± 7.6      | 0.3875          |
| Systolic blood pressure (mmHg) | 141.8 ± 17.7    | 141.5 ± 16.7    | 0.8587          |
| Total cholesterol (mmol/l)     | 5.6 ± 0.9       | 6.0 ± 0.9       | <0.001          |
| HDL cholesterol (mmol/l)       | 1.3 ± 0.3       | 1.6 ± 0.4       | <0.001          |
| LDL cholesterol (mmol/l)       | 3.7 ± 0.8       | 3.8 ± 0.8       | 0.0902          |
| Fasting glucose (mmol/l)       | 5.0 ± 0.6       | 5.0 ± 0.6       | 0.1884          |
| 2-h glucose (mmol/l)           | 6.8 ± 2.1       | 7.0 ± 1.7       | 0.0173          |
| A1C (%)                        | 5.4 ± 0.4       | 5.4 ± 0.4       | 0.6721          |
| **Follow-up (%)**              |                 |                 |                 |
| New CVD diagnosis              | 45.3            | 35.8            | 0.0245          |
| All-cause mortality            | 10.8            | 07.6            | 0.1958          |
| CVD mortality                  | 04.3            | 01.9            | 0.1101          |
| Glucose status (%)             |                 |                 | <0.001          |
| $n$                            | 168             | 258             |                 |
| Type 2 diabetes                | 26.2            | 19.0            |                 |
| IGT                            | 20.8            | 19.4            |                 |
| IFG                            | 16.1            | 07.0            |                 |
| Normal glucose tolerance       | 36.9            | 54.6            |                 |

Data are means ± SD or %.
Two-hour glucose was significantly associated with incident CVD in the IGT range (47.5% incidence; 1.65 [1.19–2.30]) and diabetic range (58.3% incidence; 2.03 [1.21–3.41]). Risk of incident CVD in women with IGT, a diabetic range of 2-h glucose, and diabetic A1C remained significant even after adjustment for BMI, smoking, blood pressure, LDL, HDL, and family history of diabetes (1.72 [1.24–2.38], 2.03 [1.21–3.41], and 2.85 [1.96–4.12], respectively). Mortality from CVD was low (n = 15, of which 9 were men); thus, subgroup analysis did not reach statistical significance.

**CONCLUSIONS** — We compared A1C, a recently proposed indicator for high risk of diabetes, with the currently used 2-h and fasting glucose as predictors of incident type 2 diabetes and CVD during 10 years. To our knowledge, this is the first study comparing the recently proposed range of elevated A1C (5.7–6.4%) with both 2-h and fasting glucose, measuring the outcome with an OGTT. Furthermore, data comparing A1C and 2-h glucose regarding future cardiovascular risk are scarce and have been focused on mortality and yielded controversial results. Here, we examined outcome of individuals with new CVD presenting to a tertiary care center, thereby adding important evidence to the use of A1C as a predictor of incident macrovascular complications in those without a history of diabetes.

Different markers detected different individuals at risk of diabetes. Importantly, a marked amount of diabetes was preceded by elevation in one of the glycemic markers only, with limited overlap among the three. Fasting and 2-h glucose reflect different pathophysiological mechanisms of abnormal glucose homeostasis (21,22). The pathophysiology of isolated IFG includes reduced hepatic insulin sensitivity, β-cell dysfunction, and reduced β-cell mass (23). With isolated IGT, peripheral insulin sensitivity is reduced with a near-normal hepatic insulin sensitivity and progressive loss of β-cell function (23). In contrast with acute-phase markers, A1C is a widely used marker of chronic glycemia, reflecting average blood glucose levels over 2–3 months.

Our results lend support to the recent suggestion that an intermediate range of
A1C may indicate high risk for type 2 diabetes (2), particularly if combined with fasting glucose (3,7). The range of A1C used in previous studies assessing the risk of future diabetes has varied, and elevated risk has been shown in ranges between 5.5 and 6.5% (6,8). A1C of 5.6–6.4% carried a hazard ratio of 13.7 for use of antidiabetes drug treatment at 3 years in Japanese (8), lending support to our findings in a similar range, but with a markedly longer follow-up period in our study. To our knowledge, this is the first longitudinal study of the nondiabetic A1C range and incident type 2 diabetes, as measured by an OGTT, in which the recently proposed A1C range of 5.7–6.4% has been evaluated.

Here, A1C, IGT, and IFG were all specific, but not sensitive, predictors of 10-year risk of type 2 diabetes. The proportion of participants who developed diabetes with IGT, elevated A1C, and IFG was observed to be similar, approximately one-third. IGT had the highest prevalence in this population, and thus the actual number of participants who developed diabetes was greatest in the IGT group. It has also been observed in the National Health and Nutrition Examination Surveys that the 2-h glucose value is more sensitive for detecting impaired glucose regulation and type 2 diabetes in elderly individuals (24).

The ultimate importance of a predictive test for type 2 diabetes is determined by its ability to indicate high risk for CVD. Risk of CVD is increased already before glycemia reaches levels of diabetes, and 2-h glucose seems to be a better predictor of CVD than fasting glucose (11).

Longitudinal data on cardiovascular risk comparing 2-h glucose and A1C in the nondiabetic range have been scarce, and results are controversial. An association was observed between 2-h glucose and, to lesser extent, between A1C and cardiovascular mortality in Dutch adults (14), but in U.S. adults, A1C was a better predictor of CVD than postchallenge glucose in women without diabetes (13). Cardiovascular mortality, however, is a late end point, and we therefore examined the incidence of new-onset CVD. In our study IGT was the only marker in the nondiabetic range significantly associated with incident CVD in women. A1C was significantly associated with incident CVD in women in the higher range of 6.5%. To our knowledge, this is the first longitudinal report comparing elevated A1C as defined by the recently proposed ADA criteria and 2-h glucose at a nondiabetic level as predictors of new-onset CVD.

Hyperglycemia was a risk factor for CVD in women but not in men, independent of BMI, smoking, blood pressure, lipids, and family history of diabetes in this age-standardized cohort. Our finding of CVD risk conveyed by hyperglycemia in women but not in men is consistent

Figure 3—Receiver operating characteristic curves for IGT, elevated A1C, and IFG. Sensitivity (Sens) and specificity (Spec) were calculated for A1C 5.7% and lower limits of IFG and IGT. For 2-h glucose AUC = 0.689, for A1C AUC = 0.659, and for fasting glucose AUC = 0.612. For differences between AUCs, P = 0.359. ●, 2-h glucose; *, A1C; Δ, fasting glucose.
Our study has several strengths. Diagnosis of CVD was confirmed from tertiary care hospital records. The broad range of CVD included coronary heart disease, ischemic stroke, carotid artery disease, and peripheral vascular disease (ICD-10 codes I00–I99). Incident diabetes was a clinical diagnosis, confirmed by two results. We investigated the predictive power of elevated A1C using the criteria recently proposed by the ADA.

Findings from this study are, however, limited because of its aging Caucasian population and generalizing them must be done with caution. Baseline CVD status was self-reported, and mild degrees of CVD cannot be excluded. We were unable to analyze CVD mortality in relation to glycemic subgroups because of the low numbers. Because samples for glucose measurements were drawn in accordance with the contemporary guidelines (WHO 1999 and WHO 2006, respectively) (16,17), capillary samples were used for 2-h glucose at baseline, but plasma was used at follow-up. It is recognized that capillary samples in the nonfasting state will give slightly higher results than venous samples (17), but the effect at the population level, with values used only for classification of glucose status and not measuring an absolute change in glucose, is likely to be marginal.

In summary, A1C and 2-h glucose, but not fasting glucose, were associated with incident CVD in women, but not in men. Among women with screen-detected diabetes, both A1C and 2-h glucose were significant predictors of incident diagnosis of CVD. Finally, among nondiabetic women, 2-h glucose was the only glycemic marker significantly associated with incident CVD.

Acknowledgments—No potential conflicts of interest relevant to this article were reported.

H.C. contributed to data collection, analyzed data, wrote the manuscript, and revised/edit the manuscript. T.S., J.J., and M.T. analyzed data, wrote the manuscript, and revised/edit the manuscript. M.L., S-K-K., and U.R. designed the study, sought approval for the study, contributed to data collection, analyzed data, wrote the manuscript, and revised/edit the manuscript. P.H. contributed to data collection, wrote the manuscript, and revised/edit the manuscript.
10. Diabetes Prevention Program (DPP) Re- 
care.diabetesjournals.org D I A B E T E S C A R E, VOLUME 33, NUMBER 9, SEPTEMBER 2010 2083

Usunmäki A, Reijula K, Kivelä SL. Preva-
13. Park S, Barrett-Connor E, Wingard DL, 
ence of diabetes mellitus and impaired 
Shan J, Edelstein S. GHb is a better pre- 
glucose tolerance in a middle-aged Fin-
dictor of cardiovascular disease than fast-
ish population. Scand J Prim Health Care 
ing or postchallenge plasma glucose in 
1995;13:222–228
women without diabetes. The Rancho 
14. de Vegt F, Dekker JM, Ruhe HG, Stehou- 
Bernardo Study. Diabetes Care 1996;19: 
èr HG, Stenh- 
450–456
15. Rajala U, Laakso M, Paivänsalo M, 
20. DeLong ER, DeLong DM, Clarke Pearson 
Pelkonen O, Suramo I, Keinanen-Kiukaanniem 
DR: Comparing the areas under two or 
i S. Low insulin sensitivity mea- 
mie s. Prevention of type 2 diabetes 
more correlated receiver-operating char- 
16. Alberti KG, Zimmet PZ. Definition, diag- 
er diabetes mellitus by changes in lifestyle among 
acteristic curves; a nonparametric ap- 
gnosis and classification of diabetes mel-
 subjects with impaired glucose tolerance. 
proach. Biometrics 1988;837–845
litis mellitus by changes in lifestyle among 
gnosis and classification of diabetes mel-
17. World Health Organization. Definition, 
subjects with impaired glucose tolerance. 
18. Consensus statement on the worldwide 
gnosis and classification of diabetes mel-
Diabetes Care 2007;30:753–759
standardization of the hemoglobin A1C 
19. Rajala U, Keinänen-Kiukaanniemi S, 
19. Faerch K, Borch-Johnsen K, Holst JJ, Vaag 
measurement. The American Diabetes As- 
24. Cowie CC, Rust KF, Ford ES, Eberhardt 
A. Pathophysiology and aetiology of im-
ciation. Geneva, Switzerland, World Health 
20. DeLong ER, DeLong DM, Clarke Pearson 
25. Hu G. Gender difference in all-cause and 
22. Nathan DM, Davidson MB, DeFronzo RA, 
21. Laakso M, Zilinskaite J, Hansen T, Boes- 
18. Consensus statement on the worldwide 
17. World Health Organization. Definition, 
16. Alberti KG, Zimmet PZ. Definition, diag-
atin sensitivity, insulin release and gluca-
Federation. Diabetes Care 1999;13:222–228
23. Faerch K, Borch-Johnsen K, Holst JJ, Vaag 
23. Faerch K, Borch-Johnsen K, Holst JJ, Vaag 
22. Nathan DM, Davidson MB, DeFronzo RA, 
21. Laakso M, Zilinskaite J, Hansen T, Boes-
15. Rajala U, Laakso M, Paivänsalo M, 
12. Selvin E, Steffes MW, Zhu H, Matsushita 
24. Cowie CC, Rust KF, Ford ES, Eberhardt 
24. Cowie CC, Rust KF, Ford ES, Eberhardt 
14. de Vegt F, Dekker JM, Ruhe HG, Stehou-
18. Consensus statement on the worldwide 
19. Rajala U, Keinänen-Kiukaanniemi S, 
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
12. Selvin E, Steffes MW, Zhu H, Matsushita 
12. Selvin E, Steffes MW, Zhu H, Matsushita 
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-
10. Diabetes Prevention Program (DPP) Re-
11. Glucose tolerance and mortality: com-
11. Glucose tolerance and mortality: com-
10. Diabetes Prevention Program (DPP) Re-